Device Performance and Parental Perception of the Skincubator 2.0, a Wearable Device to Support Prolonged Skin-to-Skin Care for Preterm Infants.

Am J PerinatolMar 18, 2026 (epub)
Clinical ResearchPediatrics

Itamar Nitzan, Raylene Phillips, Iris Morag et al.

✦ AI-curated · Sources linked

In 30 seconds

This observational study assessed transfer performance and parental perceptions of the Skincubator 2.0 during a learning phase of a feasibility study involving preterm infants. Twelve babies received care in the device across 53 sessions, including two who were invasively ventilated. The retractable transfer pad succeeded in 103 of 106 attempts, and device humidity averaged 71 ± 11%. Parents rated Skincubator skin-to-skin care (SSC) more favourably than traditional SSC for safety (p = 0.001) and convenience (p = 0.02). The findings support feasibility and parental acceptability, but do not establish effects on infant outcomes.

Key findings

  • Retractable-pad transfers succeeded in 103 of 106 attempts.
  • Humidity within the Skincubator was 71 ± 11%; average session time was 146 ± 52 minutes.
  • Parents rated Skincubator SSC safety more favourably than traditional SSC (p = 0.001).
  • Parents rated Skincubator SSC convenience more favourably than traditional SSC (p = 0.02).

Why it matters

Prolonged skin-to-skin care can be difficult to provide to extremely preterm infants because of safety concerns and practical barriers. This study reports that a wearable device designed to secure infants and their lines during transfers was usable across multiple sessions, with high transfer success and more favourable parental ratings than traditional SSC. These findings inform evaluation of approaches intended to facilitate prolonged SSC.

What to keep in mind

The study was observational and conducted during the device’s learning phase; the reported sample comprised 12 babies and 18 parents. It assessed device performance and parental perceptions, not infant clinical outcomes.

Source

Published in Am J Perinatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.